HRS-9563, an innovative siRNA Class I drug developed by Shengdi Pharmaceuticals Co., Ltd., a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd., has received clinical trial approval. The drug is designed for the treatment of hypertension, a condition that affects millions globally.
As a strategic partner, Medicilon played a strategic role in the development of HRS-9563 by providing preclinical pharmacokinetics studies and GLP-compliant safety evaluations. This approval marks another exciting milestone in the deep collaboration between Hengrui and Medicilon.
Hypertension, a high-risk chronic cardiovascular condition with a significant global prevalence, poses persistent challenges in public health. Conventional therapies often fall short in efficacy or convenience for patients. HRS-9563 addresses these limitations by precisely targeting specific genetic sequences, effectively inhibiting key proteins responsible for elevated blood pressure. This innovative approach holds promise for improving treatment outcomes.
In recent years, nucleic acid-based drugs have emerged as a focus in the biopharmaceutical field. Recognition of researchers in this domain by the Nobel Prize underscores its transformative potential. The clinical approval of HRS-9563 showcases Hengrui’s leadership in developing innovative solutions for global health challenges.
Innovation drives both Hengrui's transformation and Medicilon's commitment to the biopharmaceutical industry. To meet the growing demand for advanced nucleic acid drugs, Medicilon has established a comprehensive preclinical nucleic acid drug development platform, offering tailored services to meet the needs of the industry, from nucleic acid synthesis to in vitro screening, process optimization, and safety evaluations.
Medicilon’s expertise in nucleic acid drug R&D has solidified our reputation as a trusted partner for leading pharmaceutical companies like Hengrui. Our commitment to innovation helps accelerate groundbreaking therapies like HRS-9563, bringing them closer to clinical practice and better patient outcomes.
Medicilon congratulates Hengrui on the clinical approval of HRS-9563 and is excited about the future of this promising drug. We look forward to its continued success in clinical trials, bringing hope to patients suffering from hypertension. Moving forward, Medicilon will continue to invest in nucleic acid drug development, empowering pharmaceutical innovation and helping to accelerate the delivery of life-changing therapies to those in need.
Founded in 1970 and listed on the Shanghai Stock Exchange in 2000, Hengrui Pharmaceuticals is a leading global innovation-driven pharmaceutical company. Specializing in oncology, metabolic disorders, autoimmune diseases, respiratory conditions, and neurology, Hengrui is a top innovator in China’s pharmaceutical industry. Ranked among the Global Top 50 Pharmaceutical Companies by Pharmaceutical Executive and the Global Top 25 Pipeline Companies by Citeline in 2024, Hengrui is recognized for its dedication to improving patient care and advancing high-quality pharmaceutical development worldwide.
Founded in 2004 and headquartered in Shanghai, Medicilon (Stock Code: 688202.SH) provides end-to-end preclinical drug research services to pharmaceutical companies, research institutions, and scientists worldwide. With expertise across drug discovery, pharmaceutical research, and preclinical development, Medicilon accelerates drug development through efficient, cost-effective, and integrated services. As of June 2024, Medicilon has supported over 2,000 clients, contributing to 490 IND approvals for new and generic drugs. With a strong commitment to both global innovation and China’s pharmaceutical progress, Medicilon continues to make significant contributions to human health.
Relevant News
marketing@medicilon.com
